12:00 AM
 | 
Mar 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BIT225: Preliminary Phase Ib/IIa data

Biotron said preliminary data from a Thai Phase Ib/IIa trial in 21 treatment-naïve patients with HIV infection showed that twice-daily 400 mg BIT225 for 10 days is capable of significantly reducing...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >